ARTICLE | Financial News

Amicus prices $225M notes offering

December 16, 2016 11:24 PM UTC

Rare disease company Amicus Therapeutics Inc. (NASDAQ:FOLD) raised $225 million through the sale of 3% convertible notes due Dec. 15, 2023. The notes have an initial conversion price of $6.12, which is a 4.6% premium to Amicus' closing price of $5.85 on Wednesday before it proposed the offering. Goldman Sachs, JPMorgan, BofA Merrill Lynch, Leerink, and Cowen are underwriters (see BioCentury Extra, Dec. 15)...

BCIQ Company Profiles

Amicus Therapeutics Inc.